Hepatic metastases are amenable to ablation; however, many patients are not suitable candidates for such therapy and recurrence is common. The tumor microenvironment is known to be essential for metastatic growth, yet identification of plausible targets for cancer therapy in the microenvironment has proven elusive. We found that human colorectal cancer liver metastases and murine gastrointestinal experimental liver metastases are infiltrated by neutrophils. Plasticity in neutrophils has recently been shown to lead to both protumor and antitumor effects. Here, neutrophils promoted the growth of hepatic metastases, given that depletion of neutrophils in already established, experimental, murine liver metastases led to diminished metastatic growth. Decreased growth was associated with reductions in vascular density and branching suggestive of vessel normalization. Metastasis-associated neutrophils expressed substantially more fibroblast growth factor 2 (FGF2) than na€ ıve neutrophils, indicating neutrophil polarization by the tumor microenvironment. Administration of FGF2 neutralizing antibody to mice bearing experimental liver metastases phenocopied neutrophil depletion by reducing liver metastatic colony growth, vascular density, and branching. Conclusion: Here, we show, using FGF2 as an example, that identification of factors responsible for the protumoral effects of infiltrating myeloid cells can be used to target established liver metastases. Such therapies could be utilized to limit disease progression and potentiate the effects of standard ablative therapies. (HEPATOLOGY 2017;65:1920-1935.
Hepatic metastases are amenable to ablation; however, many patients are not suitable candidates for such therapy and recurrence is common. The tumor microenvironment is known to be essential for metastatic growth, yet identification of plausible targets for cancer therapy in the microenvironment has proven elusive. We found that human colorectal cancer liver metastases and murine gastrointestinal experimental liver metastases are infiltrated by neutrophils. Plasticity in neutrophils has recently been shown to lead to both protumor and antitumor effects. Here, neutrophils promoted the growth of hepatic metastases, given that depletion of neutrophils in already established, experimental, murine liver metastases led to diminished metastatic growth. Decreased growth was associated with reductions in vascular density and branching suggestive of vessel normalization. Metastasis-associated neutrophils expressed substantially more fibroblast growth factor 2 (FGF2) than na€ ıve neutrophils, indicating neutrophil polarization by the tumor microenvironment. Administration of FGF2 neutralizing antibody to mice bearing experimental liver metastases phenocopied neutrophil depletion by reducing liver metastatic colony growth, vascular density, and branching. Conclusion: Here, we show, using FGF2 as an example, that identification of factors responsible for the protumoral effects of infiltrating myeloid cells can be used to target established liver metastases. Such therapies could be utilized to limit disease progression and potentiate the effects of standard ablative therapies. (HEPATOLOGY 2017; 65:1920 -1935 ).
SEE EDITORIAL ON PAGE 1796
A t least one third of colorectal cancer patients develop liver metastases, (1) and death from colorectal cancer is usually attributable to metastatic disease. Treatment for liver metastases centers upon ablation, with surgical resection or radiation to oligometastatic disease the most frequently used methods, albeit ones that are only technically available to a subset of patients. These treatments are sometimes followed by long-term survival, but over one half of patients develop recurrence within 2 years of treatment. (2) Biological understanding of these metastases and their recurrence may provide much needed strategies for treatment.
The transition from preangiogenic to macroscopic metastasis is a rate-limiting step in the hepatic metastatic cascade, (3) identifying development of an angiogenic phenotype as a key factor for metastatic progression within Abbreviations: APC, allophycocyanin; CCR, C-C chemokine receptor; cDNA, complementary DNA; Col5a1, collagen type V alpha 1 chain; Ct, threshold cycle; CXCR, C-X-C motif chemokine receptor; DAPI, 4 0 ,6-diamidino-2-phenylindole; ECM, extracellular matrix; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescence-activated cell sorting; FGF2, fibroblast growth factor 2; FSC, forward scatter; GFP, green fluorescent protein; G-MDSCs, granulocytic myeloid-derived suppressor cells; Ig, immunoglobulin; IHC, immunohistochemistry; PE, phycoerythrin; SCID, severe compromised immunodeficiency; SSC, side scatter; TGF, transforming growth factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. the liver. Immune cells can promote cancer progression through various mechanisms, including the stimulation of angiogenesis, (4) and can exhibit a protumorigenic phenotype driven, in part, by tumor-derived factors. (5) Neutrophils are one such "plastic" immune cell type that undergo polarization within the tumor microenvironment (6) and that have known angiogenic activity. Neutrophils are found in abundance within many kinds of tumors, including colorectal cancer, (7) and in colon cancer patients, neutrophilia predicts reduced cancer-free survival and metastatic progression. (8) Neutrophils have been identified at various steps in the hepatic metastatic cascade. Before cancer cell seeding, livers of mice bearing gastrointestinal tumors are infiltrated with prometastatic neutrophils. (9, 10) Neutrophils promote hepatic tumor cell retention through the formation of neutrophil extracellular traps (11) and neutrophil depletion before tumor cell challenge inhibits metastatic development. (12) Neutrophils also contribute to the establishment of a metastatic niche in pancreatic liver metastases, (13) and neutrophil infiltration early in the formation of liver metastases in mice was shown to play a role in the recruitment of a subset of macrophages, fibrocytes, that also facilitated metastasis formation. (14) However, a role for neutrophils within established hepatic metastasis is yet to be examined. Given the advanced stage of hepatic metastasis at the time of diagnosis, identification of factors promoting continued tumor growth could have significant clinical relevance.
Materials and Methods

CELL CULTURE AND LENTIVIRAL TRANSFECTION
HT29, HCT-116, LoVo, Pan02, and KPC cells were grown in RPMI under sterile, mycoplasma-free conditions. Cells were discarded after the eighth passage. Cell line authentication was performed using Short Tandem Repeat profiling (Cancer Research UK genomic facility, Leeds Institute of Molecular Medicine, March 2014). Human cell lines were transfected with lentivirus containing the firefly luciferase and green fluorescent protein (GFP) genes under puromycin selection (Capital Bioscience, Rockville, MD). For the generation of stable fibroblast growth factor 2 (FGF2) overexpressing cell lines, the FGF2 gene sequence comprising only the coding region for the 18-kDa low-molecular-weight form of FGF2 was inserted into a plasmid containing the hygromycin resistance gene (System Biosciences No. cd515B1-1, California, USA). Lentivirus containing the plasmid was then transfected into HT29. which were subsequently selected with hygromycin. 
ANIMAL WORK
FLOW CYTOMETRY AND CELL SORTING
Single-cell suspensions were generated from murine livers as described. (15) Suspensions at a concentration of 10 7 cells/mL were incubated at room temperature (45 minutes) in combinations of the following antibodies in the presence of Fc blocking antibody:
systems, Minneapolis, USA), anti-CCR3-PE, and anti-CCR4-PE (both BioLegend). Analysis was performed using FlowJo software. The percentage of positive cells within samples was determined, and the total number of cells of interest per organ was calculated. For sorting of CD45 1 /CXCR2 1 neutrophils from normal and tumor-bearing livers, single-cell hepatic suspensions pooled from 6 tumor-bearing or control mice were stained with anti-CD45-PE and anti-CXCR2-APC as above, before being fluorescence-activated cell sorting (FACS) sorted using a high-speed cell sorter (Beckman Coulter, High Wycombe, UK).
In vivo administration of the neutrophil depleting antibody 1A8 may mask the Ly6G epitope, making it impossible to subsequently identify neutrophils. We therefore used a combination of CD45 and CXCR2 to identify neutrophils in animal experiments where neutrophil depletion was performed.
ISOLATION OF HIGH-AND LOW-DENSITY NEUTROPHILS FROM MOUSE BLOOD
We followed the protocol described by Sagiv et al. (16) Briefly, whole blood was collected in heparinized syringes by cardiac puncture. Blood was diluted in phosphate-buffered saline containing 0.5% bovine serum albumin (Sigma-Aldrich, Missouri, USA) and then centrifuged at 228C, 700g for 30 minutes on a discontinuous Histopaque (Sigma-Aldrich) gradient (1.119 and 1.077). The high-and low-density fractions were resuspended in hypotonic lysis buffer before staining with the appropriate FACS antibodies.
GENE PROFILING OF HEPATIC CELL POPULATIONS
RNA was extracted from FACS sorted cells using TRIzol reagent (ThermoFisher Scientific, Massachussets, USA), before complementary DNA (cDNA) synthesis. For analysis of angiogenic factors produced by neutrophils, gene expression was determined using predesigned PCR array plates (PAMM-072Z; SABiosciences). cDNA samples were loaded in duplicate before being analyzed using SYBR green technology in a qPCR machine (Stratagene). Gene expression was compared between neutrophils from healthy livers and those from livers bearing HT29, HCT-116, or LoVo hepatic metastases by way of the DDCt (threshold cycle) method after normalization to housekeeping genes. For the comparison of FGF2 mRNA expression level in various cell types, FACS sorted from the tumor microenvironment cDNA was generated from cells as above before incubation with murine (CTGGCTTCT AAGTGTGTTAC forward and GAAGAAACAGT ATGGCCTTC reverse) or human FGF2 (TGGC TTCTAAATGTGTTACG forward and GTTTAT ACTGCCCAGTTCG reverse) primers and analyzed as above.
IMMUNOHISTOCHEMISTRY AND ENZYME-LINKED IMMUNOSORBENT ASSAY
Livers were embedded in optimal cutting compound and frozen in liquid nitrogen. Then, 12-lm tissue sections were cut and fixed in 4% paraformaldehyde or acetone. Tissues were blocked in serum of the same species as the secondary antibody before incubation in primary antibody for 2 hours at room temperature. Tissues were then incubated in fluorochromeconjugated secondary antibodies for 1 hour at room temperature before counterstaining with 4 0 ,6-diamidino-2-phenylindole (DAPI). Stained tissues were visualized using a laser scanning confocal microscope (LSM710; Carl Zeiss, Oberkochen, Germany) For the human FGF2 enzyme-linked immunosorbent assay (ELISA) on mouse serum, we used a commercially available ELISA kit (BioLegend No. 434311, San Diego, California, USA). Serum was diluted 2-fold before addition to the ELISA plate, and the protocol was followed as per the manual.
HUMAN SPECIMENS
Human hepatic metastases were obtained from the Oxford Radcliffe Biobank following institutional review and granting of ethical approval. Tumorsresected with curative intent-and surrounding unaffected liver were obtained from 33 patients for IHC analysis. Neutrophil counts and FGF2 staining intensity within neutrophils were quantified using ImageJ (National Institutes of Health).
WESTERN BLOTTING
Protein was extracted from homogenized murine hepatic metastases with care taken to exclude normal surrounding liver. Homogenates were incubated in protease inhibitor (Cell Signalling, Danvers, USA) diluted in radioimmunoprecipitation assay buffer (Sigma-Aldrich) for 30 minutes at 48C with agitation before centrifugation at 15,000rpm for 15 minutes.
Protein concentration was confirmed by bicinchoninic acid assay before heating 20 ug of protein in Laemlli buffer at 1008C for 10 minutes. Samples were run on 4%-12% Bis-Tris gels for 90 minutes at 120 V. Following transfer, nitrocellulose membranes were blocked in 5% milk before incubation overnight at 48C in a 2% milk solution containing 2 ug/mL of monoclonal anti-FGF2 antibody (05-118; Millipore). After washing, membranes were incubated horseradishperoxidase-conjugated secondary antibodies before being developed in enhanced chemiluminescence and visualized using the Odyssey Imaging System (Licor).
STATISTICAL ANALYSIS
Statistical analyses of flow cytometry data, IHC staining, and tumor burden were performed using GraphPad Prism 5.0 software (GraphPad Software Inc). The Student t test was used to compare means in normally distributed data. Paired Student t tests were used for the comparison of values from human hepatic metastases and matched, unaffected liver, and the Mann-Whitney U test was used to compare median distances between Ly6G 1 cells and vessels or DAPI 1 cells and vessels. Vessel branch points were quantified using Angioquant software (http://www.cs.tut.fi/sgn/ csb/angioquant/). The distance between neutrophils and vessels was determined using Imaris V8.1 (http:// www.bitplane.com/) and neutrophil FGF2 intensity quantified as described. (17) Calculation of staining area in IHC experiments was determined using ImageJ (National Institutes of Health). A P value of <0.05 was considered statistically significant throughout, all data analyzed were of a continuous nature, and error bars represent SD throughout. 
Results
HEPATIC METASTASES FROM GASTROINTESTINAL TUMORS ARE INFILTRATED WITH NEUTROPHILS
In previous work, we identified the recruitment of monocytes to liver metastases in immunocompetent mice. However, here, within human liver metastases, we found substantial neutrophil infiltration compared to matched surrounding, uninvolved liver tissue (Fig.  1A) . On average, and in each individual case, metastases had significantly greater infiltration of neutrophils than the adjacent liver (Fig. 1B,C) . These observations suggested that neutrophils might contribute to the biology of hepatic metastasis.
To determine whether similar neutrophil infiltration occurred in murine models of human liver metastasis, we used intrasplenic injection of human colorectal cancer cells to seed livers of immunosuppressed mice. The resulting liver colonies from three human colorectal cell lines were infiltrated with neutrophils (Ly6G 1 cells), with many fewer in the adjacent noncancerous liver or na€ ıve normal liver (Fig. 1D) .
We sought to characterize these cells in flow cytometry after disaggregation of murine livers. These cells were CD11b high /Gr1 high and were found in significantly higher numbers in livers of tumor-bearing compared to control mice (Supporting Fig. S1A ,C). They were CXCR2 positive, but did not express other CC or CXC receptors tested (CCR1-5 and CXCR3-7; Supporting Fig. S1C ). Neutrophil depletion in SCID mice using the neutrophil-specific anti-Ly6G (clone 1A8) antibody resulted in a near-complete reduction in CD45
neg cells (Supporting Fig S2A,B) . SCID mice lack other cell types expressing CXCR2, such as T lymphocytes, so neutrophils in this strain can therefore be defined by their CD45
1 expression. In keeping with the IHC data, disaggregated livers from SCID mice bearing colorectal cancer-cellderived metastases demonstrated significantly greater CD45 1 /CXCR2 1 neutrophil infiltrates compared to na€ ıve livers (Fig. 1E,F) . FACS sorted CD45 1 / CXCR2
1 cells from HT29 liver metastases demonstrated the multilobed nuclei unique to neutrophils and higher forward/side scatter (FSC/SSC) flow cytometry parameters than CD45
1
/CXCR2
1 monocytic cells from the same metastases (Fig. 1G) . We also identified almost universal expression of CXCR2 on the Ly6G 1 cell population in HT29 and HCT-116 liver metastases (Supporting Fig. S1B ), further supporting the specificity of CD45/CXCR2 for the identification of neutrophils in this setting.
To ask whether similar infiltrates developed in liver colonies in syngeneic models for liver metastasis, we generated liver colonies from murine pancreatic cancer cell lines in syngeneic C57Bl6 mice. These also contained significantly larger neutrophil infiltrates than na€ ıve C57Bl6 livers (Fig. 1H-J) . Thus, recruitment of neutrophils in murine liver metastases from murine cell lines was also evident in immune-competent hosts.
Neutrophils are typically found in the high-density fraction of blood separated on a Histopaque gradient. However, recent analysis of the blood of tumorbearing animals and humans has identified an immature neutrophil population with an immunosuppressive phenotype found in the low-density fraction. (16) In order to determine whether the neutrophils identified our models were high or low density, we subjected blood from na€ ıve mice and those bearing HT29, HCT-116, or KPC hepatic metastases to discontinuous density gradients. Interestingly, we found no significant differences in the CD11b
1
/Ly6G
1 cell population in the low-density fraction from na€ ıve and tumor-bearing mice (Supporting Fig. S1E,F) . The difference in our findings and those by Sagiv et al. may result because our models involve different cell lines at different locations and the mice have undergone splenectomy and the spleen is a known reservoir for immunosuppressive neutrophil populations. (18) 
NEUTROPHIL DEPLETION INHIBITS THE GROWTH OF HEPATIC COLORECTAL AND PANCREATIC CANCER METASTASIS
Given the significant neutrophil infiltrates identified in established human metastases and the protumorigenic role identified for neutrophils in other cancer types, we next asked what effect neutrophil depletion would have on metastatic liver colony growth. Depletion of neutrophils before liver colony seeding using breast (19) or lung cancer cells (12) greatly reduced liver colony formation through mechanisms including adhesion between neutrophils and tumor cells in the hepatic sinusoid (12) and neutrophil extracellular trap formation. (11) To avoid these potential effects on cancer cell seeding in the liver, we depleted neutrophils after the tumor cells were injected and therefore after seeding had occurred to determine the effect of neutrophils on subsequent colony expansion and growth.
We followed the fate of the tumor cells expressing firefly luciferase following intrasplenic injection by in vivo bioluminescence imaging at sequential time points. Initially, the signal fell as would be expected from metastatic inefficiency. The trough was reached by 7-10 days, and by 12 days the hepatic bioluminescence signal steadily increased ( Fig. 2A) . At 7 days, metastatic deposits of 80-100 lm in diameter (with several hundreds of cells) were evident, often with small neutrophil infiltrates even at this early stage (Fig.  2B ). Because early colonies had begun to grow in these experiments by day 7 after intrasplenic injection, we reasoned that neutrophil depletion from this point onward would allow analysis of the effect of neutrophils on the growth of established metastases independent of seeding. Strikingly, neutrophil depletion starting 7 days after colon or pancreatic cancer cell injection significantly inhibited metastatic development (Fig. 2C-E) . Neutrophil depletion from 14 days following tumor cell injection had a similar effect on metastatic growth, whereas if started at 21 days, a growth inhibitory effect was not evident (Supporting Fig. S2F ). Given the recently reported difficulty in successful depletion of neutrophils in murine liver and tumor tissues, (20) we analyzed livers of isotype control and anti-Ly6G-treated, tumor-bearing mice at the end of these experiments to confirm neutrophil depletion. Neutrophil depletion by regular administration of anti-Ly6G persisted until the end of the experiments (Supporting Fig. S2C,D) . These data indicate that neutrophils promote the growth phase of hepatic metastases in immunosuppressed and immunocompetent models, in support of evidence demonstrating a role for CXCR2-expressng neutrophils in the promotion of pancreatic cancer metastasis. (13) 
NEUTROPHIL DEPLETION INHIBITS TUMOR PROLIFERATION AND INTRATUMORAL ANGIOGENESIS
Under certain circumstances, neutrophils promote tumor angiogenesis; however, they have not been linked to angiogenesis specifically in the hepatic metastatic microenvironment. We assessed the vasculature in hepatic metastases using IHC. In liver metastases from neutrophil-depleted mice, vascular density was significantly lower than in metastases from control animals (Fig. 3A,B) . Proliferation of tumor cells in the liver colonies, as judged by Ki-67 staining, was also reduced in metastases from neutrophil-depleted mice, consistent with the decrease in metastatic growth (Fig. 3C,D) .
Proposed mechanisms through which neutrophils promote angiogenesis include release of extracellular matrix (ECM)-bound angiogenic factors (21) and the expression of proangiogenic factors such as vascular endothelial growth factor (VEGF). (22) Consistent with a role in angiogenesis, neutrophils can be found in a perivascular location in developing tumors. (23) In keeping with this finding, we found many perivascular neutrophils in established hepatic metastases from HT29 colon cancer cells (Supporting Fig. S3A ). To quantify the position of the neutrophils in relation to the vessels and thereby determine whether neutrophils reside primarily in the perivascular space, we used Imaris image analysis software to measure the distance between each neutrophil and the nearest CD31 1 vessel. We then compared this distance to the average distance between every DAPI 1 cell within the tumor and its nearest CD31 1 blood vessel (Supporting Fig. S3B ). Neutrophils were significantly closer to vessels than the average cell in the tumor (Supporting Fig. S3C ), indicating that they reside in proximity to the developing tumor vasculature. This would be the ideal position in which neutrophils could promote angiogenesis through deposition of angiogenic factors in the vascular basement membrane. Similar patterns of neutrophil distribution were also present in HCT-116 and LoVo metastases (data not shown), and we did not observe neutrophil infiltrates, in particular at the invasive edge of liver metastases.
TUMOR-CONDITIONED NEUTROPHILS EXPRESS PROANGIOGENIC FACTORS
In order to determine whether the neutrophils identified in hepatic metastases express factors capable of promoting angiogenesis, we compared mRNA expression profiles of neutrophils sorted by FACS from tumor-bearing and na€ ıve livers. FGF2, Fibronectin, and SerpinE1 expression were all increased >10-fold in neutrophils from hepatic metastases of all three human colorectal cancer cell lines compared to neutrophils from na€ ıve livers (Fig. 4A) , whereas VEGF was not substantially altered. FGF2 was of particular interest, given that it is a highly angiogenic molecule capable of promoting both the proliferation and migration of endothelial cells in various tumor models, as well as acting synergistically with other factors to promote angiogenesis. (24) Once secreted, FGF2 binds to heparin sulfate glycosaminoglycans in the ECM, (25, 26) and ECM proteolysis facilitates the release of dimeric FGF2, enabling receptor binding and activation. (27) It was therefore of interest that the mRNA for heparanase, an enzyme that can release FGF2 from the ECM, was also consistently elevated in tumorconditioned neutrophils (Fig. 4A) .
We next asked which cells in the hepatic tumor microenvironment expressed the highest levels of FGF2 mRNA. CD11b
1
/Gr1
1 cells, the population that comprises the neutrophils from hepatic metastases, expressed significantly higher levels of FGF2 mRNA compared with GFP -/Gr1 -; Fig. 4B ). Consistent with the suggestion that tumor-infiltrating neutrophils were the main source of FGF2, hepatic metastases in mice depleted of neutrophils demonstrated a striking reduction in FGF2 protein when compared to metastases from control mice (Fig. 4C) .
Within hepatic metastases, FGF2 was identified by IHC in two distinct locations; the neutrophils and the ECM (Fig. 4D-F) . Most neutrophils in the murine liver metastases identified by Ly6G expression costained for FGF2 (Fig. 4D) . In addition to expression in neutrophils, FGF2 was also observed in thick bands, consistent with deposition within the ECM (Fig. 4D) . Costaining for FGF2 and collagen type V alpha 1 chain (Col5a1), a major component of tumoral ECM, demonstrated a high degree of colocalization (Fig.  4E) , confirming extracellular FGF2 deposition.
In keeping with our RNA analysis, we observed minimal FGF2 staining in tumor cells (Fig. 4D) . Finally, human hepatic metastases and uninvolved liver from the same patients were costained for CD66b and FGF2 (Fig. 4F) . There was increased FGF2 staining intensity within tumor-associated neutrophils compared to neutrophils in the uninvolved adjacent liver (Fig. 4G) , consistent with our findings in mice.
FGF2 INHIBITION DELAYS TUMOR GROWTH IN ASSOCIATION WITH VASCULAR NORMALIZATION
To explore the role of FGF2 for metastatic growth in the liver, we asked what effect administration of a monoclonal FGF2 blocking antibody (GAL-F2) would have on colony growth. This antibody has previously been shown to inhibit hepatocellular carcinoma xenograft growth by blocking the autocrine growth effect of FGF2 on the carcinoma cells. (28) In our experiments, however, recombinant FGF2 had no mitogenic activity in colon cancer cells in vitro (Supporting Fig. S4A) , and GAL-F2 failed to inhibit the basal proliferation of HT29 or HCT-116 cells, while having only a small antiproliferative effect on LoVo cells (Supporting Fig. S4B ), suggesting that FGF2 does not promote the growth of hepatic metastases through direct effects on the tumor cells. Furthermore, liver metastases in mice treated with GAL-F2 demonstrated heavy neutrophil infiltrates just as in control mice (Supporting Fig. S4C ), indicating that FGF2 inhibition in vivo did not affect neutrophil recruitment or survival within the metastatic microenvironment.
GAL-F2 was then administered to mice 1 week following intrasplenic injection of pancreatic or colonic cancer cells and was continued every 48 hours. This resulted in a reduction in metastatic burden as determined by the number and size of macroscopic hepatic metastases (Fig. 5A,B) . The average size was diminished for the experiments with Ht29 and LoVo, but not KPC. Vascular density and proliferation were reduced in tumors from mice treated with GAL-F2 (Fig. 5C,D) and there was a striking alteration in vascular structure, suggesting reduced vessel branching in metastases from GAL-F2-treated mice. This impression was supported by computer-aided vessel branch-point analysis, which demonstrated a significant reduction in vascular branch-point number in response to GAL-F2 treatment (Fig. 5E) .
These morphological findings are consistent with changes sometimes termed vascular normalization, whereby vessels are remodeled resulting in improved oxygen delivery. (29) In keeping with these observations, tumors from GAL-F2-treated mice displayed a significant reduction in hypoxia compared to those from control animals (Fig. 5F ). This result suggests improved vascular function leading to improved tumor oxygenation, despite reduced overall vessel density. Tumor hypoxia is associated with a more aggressive phenotype, increased cancer cell migration, and, ultimately, tumor invasion. In keeping with this, metastases from GAL-F2-treated mice had a well-circumscribed tumor-liver interface, whereas control metastases had an irregular border with frequent tumor protrusions into the normal liver, suggestive of enhanced invasion (Fig. 5G) . A decrease in branching was also evident in the liver metastases from neutrophil-depleted mice compared to controls (Supporting Fig. S2E ), supporting the concept that neutrophils promote a disorganized tumor vasculature.
Taken together, these data suggest that neutrophils expressing FGF2 promote the development of a disorganized tumor vasculature and tumor hypoxia. Inhibition of FGF2 or neutrophil depletion reversed this effect, normalized tumor vasculature, and inhibited metastatic growth.
We asked whether neutrophils promote the growth of liver metastasis predominantly through FGF2 expression. HT29 cells were transfected with a lentiviral construct driving overexpression of the 18-kDa FGF2 (HT29-FGF2o/e) secreted form, but which does not generate the higher-molecular-weight, nuclear nonsecreted forms. In mice bearing FGF2-overexpressing tumors, circulating FGF2 levels were elevated (Fig. 5I) . We found a small, significant increase in tumor burden in mice bearing HT29-FGF2 liver metastases compared to the lentiviral control cell line (Fig. 5H) . In analogy to the results described above, neutrophil depletion significantly reduced metastatic burden in lentiviral control tumors. Neutrophil depletion, however, had no effect on the growth of tumors in mice injected with the HT29-FGFo/e cell line (Fig. 5E) . Tumors from the FGF2-overexpressing cell line demonstrated increased vascularity compared to those from lentiviral control cells, and tumor vascularity was not reduced by neutrophil depletion in FGF-overexpressing tumors (Supporting Fig. S4D ). FGF2 expression in tumor cells thereby rescues metastatic growth in the face of neutrophil depletion, indicating that the primary prometastatic function of neutrophils in our model is FGF2 expression.
Discussion
Through the analysis of relevant murine models, as well as human tissue specimens, we have demonstrated that neutrophils drive metastatic angiogenesis and ultimately tumor growth. FGF2 expression is responsible for the development of a disorganized vasculature in hepatic metastases, tumor hypoxia, and an invasive cancer cell phenotype. Depletion of neutrophils, once metastases were initiated, reduced FGF2 expression and suppressed angiogenesis and tumor growth. In humans, hepatic metastases have developed an angiogenic phenotype by the time of diagnosis and angiogenesis is required for disease progression. Treatment modalities targeting angiogenic mechanisms in liver metastasis are therefore of significant clinical relevance.
Previous analyses of tumor-associated neutrophils have demonstrated remarkable plasticity from a cell that was historically felt to possess a relatively limited functional repertoire. Given that neutrophils have been increasingly studied in the context of cancer and its immune response, it is evident that there are a variety of distinctive myeloid entities, some with granulocytic characteristics that overlap markers with neutrophils. Currently, the distinctions are just beginning to be defined and understood. (30) Whereas coexpression of Gr1 and CD11b defines granulocytic myeloid-derived suppressor cells (G-MDSCs)-a population that also promotes tumor progression and metastasis (31) -the definition of G-MDSCs rests, in part, on their ability to suppress antitumor T-cell responses, as well as their expression of factors such as tumor necrosis factor (TNF)-a and arginase. (32) Although it is possible that the CD45
1
/CXCR2
1 cells identified here are indeed G-MDSCs or that these are overlapping subsets of myeloid cells, they did not express consistently high levels of TNF-a and had the nuclear morphology characteristic of neutrophils.
Neutrophils become protumorigenic in response to tumor-derived chemokines, such as transforming growth factor (TGF)-b, (6) and tumor-associated neutrophils display enhanced expression of several immunosuppressive factors. (33) Indicative of their plasticity, however, tumor-conditioned neutrophils also stimulate antitumor immunity in early-stage lung cancer (34) and can inhibit seeding of tumor cells in the premetastatic lung, (35) whereas tumor-conditioned neutrophils can facilitate metastatic growth in breast cancer lung metastases through the synthesis of leukotrienes. (36) Alternatively, neutrophils expressing CXCR2 are important for metastatic initiation in the liver, where they promote accumulation of protumorigenic fibrocytes (13) or retention of tumor cells in the hepatic sinusoid during seeding. (11, 12) In our experiments in immunosuppressed mice as well as immunocompetent mice, neutrophils were recruited to the liver colonies. And, in each case, their depletion reduced colony growth and FGF2 deposition while blocking FGF2-altered tumor vascular morphology.
Although we cannot be certain that the ECMdeposited FGF2 is derived solely from tumorassociated neutrophils, we found them to be the primary source of FGF2, both at the RNA and protein level, with little or no FGF2 expression demonstrated within tumor cells. Furthermore, tumors grown in neutrophildepleted mice were deficient in FGF2. Interestingly, neutrophils from the metastases of all three cell lines also displayed enhanced expression of heparanase, an enzyme whose activity generates the release of angiogenic FGF2 from ECM glycosaminoglycans. (37) Thus, as well as directly producing FGF2, tumor-associated neutrophils may promote FGF2 activity by facilitating its release from the ECM.
VEGF promotes angiogenesis in colorectal cancer (38) ; however, patients with metastatic colorectal cancer demonstrate variability in their response to VEGF inhibition, indicating the existence of several overlapping angiogenic mechanisms. Anti-VEGF resistance is driven, in part, by the activity of Gr1 1 cells recruited to the tumor microenvironment (39) ; however, FGF2 has also been implicated in disease relapse following failure of VEGF inhibition in the setting of glioblastoma. (40) In vitro, splenic CD11b
1 cells express FGF2 in response to tumorconditioned media (41) ; however, ours is the first evidence demonstrating FGF2 expression in neutrophils within the tumor microenvironment. These points indicate the potential value of FGF2 inhibition for patients with hepatic metastasis, and suggest that FGF2 inhibition may also be of value to patients resistant to anti-VEGF therapy.
As well as demonstrating a reduction in tumor vasculature in GAL-F2-treated mice, we also identified a striking change in vessel morphology, whereby FGF2 inhibition resulted in a vascular network with less branch points and reduced tumor hypoxia, suggesting improved perfusion. Although counterintuitive, the idea that such vessel normalization and improved oxygenation should delay tumor growth is well recognized and has been demonstrated in several experimental settings. (42, 43) Such vascular remodeling has previously been demonstrated following inhibition of VEGF or placental growth factor signaling in tumor-bearing mice (44, 45) ; however, this is the first time that vascular normalization has been linked to FGF2 expression within the tumor microenvironment. Vascular normalization and improved oxygenation promotes chemosensitivity (46) ; however, FGF2 inhibition as a chemosensitizing agent has not yet been explored. Chemotherapy is the mainstay of treatment for patients with inoperable liver metastases and is able to increase operability through downstaging. Treatments that enhance the effect of chemotherapy would be of immense benefit, and a potential role for FGF pathway inhibition in this setting therefore merits investigation.
Despite our evidence showing that FGF2 promotes angiogenesis in liver metastasis, we recognize that we have not identified an underlying mechanism for this effect and that FGF2 is a highly pleotropic growth factor. Indeed, it is equally possible that FGF2 also promotes metastatic growth through mechanisms independent of angiogenesis and by action on cells other than the endothelia or their supporting cells. FGF2 induces an inflammatory response in endothelial cells that leads to the recruitment of various immune cell subsets. (47) Neutrophils, for example, express FGFR2, and FGFR2 inhibition diminishes FGF2-mediated neutrophil chemotaxis.
(48) Although we did not detect a quantitative difference in the neutrophil infiltrate in tumors from GALF2-treated mice compared to controls, it is possible that FGF2 inhibition altered the phenotype of recruited neutrophils.
We developed liver metastases in mice using the well-documented technique of intrasplenic injection. Although this method ignores the contribution that a premetastatic niche or the release of tumor cells from a primary tumor have on disease progression, we were interested in the role of neutrophils in the growth of established hepatic metastases. In the setting of established metastasis, the contribution of a primary tumor or premetastatic niche is less important. Furthermore, we found substantial infiltration of neutrophils in human material, suggesting that liver metastasis from colonic cancers in humans share some features with the animal model used here.
In summary, our data identify FGF2 production as a mechanism through which neutrophils promote angiogenesis and thereby growth of liver metastases. As such, we have identified several potential targets for the inhibition of liver metastatic growth, a process with few effective therapeutic options. Future work should concentrate on the role that FGF2 plays in the promotion of hepatic metastatic angiogenesis and, in particular, whether, through vascular normalization and improved tumor perfusion, FGF2 inhibition could be used as a mechanism for enhancing chemotherapeutic downstaging or prevention of recurrence after resection.
